Going beyond gene edited CARs
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
9 hidden Gems from the ASH21 poster hall and why you should pay attention to them
A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study
Part 2 of our mini-series on Next Generation CAR-T cells
Overcoming the limitations associated with CAR-T performance and lack of persistence
Several controversies abound in the CAR-T cell niche this year, plus what's coming next?
Key learnings and highlights from the recent AACR DLBCL specialist meeting
